General Information of DTT (ID: TTGN1ZA)

DTT Name Angiotensin II receptor (AGTR) DTT Info
Gene Name AGTR

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
2 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CYT-006-AngQb DMIRSWE Hypertension BA00-BA04 Phase 2 [1]
DA-727 DM9KS1A Hypertension BA00-BA04 Phase 1 [2]
------------------------------------------------------------------------------------
26 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBR-363 DMGWFZJ Hypertension BA00-BA04 Discontinued in Phase 2 [3]
E-4177 DM2G7IP Hypertension BA00-BA04 Discontinued in Phase 2 [4]
Elisartan potassium DM0XF8J Hypertension BA00-BA04 Discontinued in Phase 2 [5]
ETRX-101 DMRB23N Anemia 3A00-3A9Z Discontinued in Phase 2 [6]
FK-739 DM7TLF6 Hypertension BA00-BA04 Discontinued in Phase 2 [7]
ICI-D-8731 DM3R8TX Hypertension BA00-BA04 Discontinued in Phase 2 [8]
CGP-48369 DMY8KO4 Hypertension BA00-BA04 Discontinued in Phase 1 [9]
DuP-532 DM59WQ7 Hypertension BA00-BA04 Discontinued in Phase 1 [10]
ICI-D-6888 DMZYA9E Hypertension BA00-BA04 Discontinued in Phase 1 [11]
A-81282 DMH6LCD Hypertension BA00-BA04 Terminated [12]
A-81988 DM1GLIN Hypertension BA00-BA04 Terminated [13]
BIBS-222 DM5107E Hypertension BA00-BA04 Terminated [14]
BIBS-39 DM098BL Hypertension BA00-BA04 Terminated [14]
BMS-180560 DMWDRI0 Hypertension BA00-BA04 Terminated [15]
CI-996 DMCJ7N1 Hypertension BA00-BA04 Terminated [16]
DMP-811 DMO26E7 Hypertension BA00-BA04 Terminated [17]
EXP-6803 DM9P4ZN Hypertension BA00-BA04 Terminated [18]
FR-149581 DMBOFSQ Hypertension BA00-BA04 Terminated [19]
KW-3433 DMS2KEG Hypertension BA00-BA04 Terminated [20]
L-163017 DMYB5RV Hypertension BA00-BA04 Terminated [21]
ME-3221 DMHX6IC Hypertension BA00-BA04 Terminated [22]
RWJ-46458 DMEO7YD Hypertension BA00-BA04 Terminated [23]
SC-51316 DMB26LO Hypertension BA00-BA04 Terminated [24]
SL-910102 DMNTGXQ Hypertension BA00-BA04 Terminated [25]
WAY-126227 DMTY7PE Hypertension BA00-BA04 Terminated [23]
ZD-7155 DM5KSCI Hypertension BA00-BA04 Terminated [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 Discontinued Drug(s)
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
A-82186 DMQ5AJW Hypertension BA00-BA04 Investigative [27]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
2 WO patent application no. 2009,0880,06, Combined pharmaceutical agent.
3 Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol. 1999 October; 48(4): 594-604.
4 Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84.
5 Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995 Apr 15;75(12):793-5.
6 WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
7 The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. Jpn J Pharmacol. 1993 Nov;63(3):335-43.
8 Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7.
9 Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994 May;89(5):2212-8.
10 DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69.
11 WO patent application no. 1995,0216,09, Treatment of normotensive glaucoma with angiotensin ii antagonists.
12 Pharmacological characterization of Abbott-81282, a novel, non-peptide angiotensin-II antagonist selective for type-1 receptors. Life Sci. 1993;53(11):929-37.
13 [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54.
14 Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41.
15 BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol. 1994 Sep;113(1):179-89.
16 Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther. 1995 Mar;272(3):963-9.
17 Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee. Drug Metab Dispos. 1995 Oct;23(10):1104-9.
18 Nonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803. Hypertension. 1989 May;13(5):489-97.
19 US patent application no. 2003,0087,306, Methods for identifying novel multimeric agents that modulate receptors.
20 Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull. 2001 Jun;24(6):628-33.
21 In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Eur J Pharmacol. 1995 Dec 29;294(2-3):439-50.
22 Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1996 Mar;23(3):229-35.
23 WO patent application no. 1996,0402,58, Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure.
24 In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther. 1992 Jun;261(3):1037-43.
25 A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24.
26 Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat. J Pharm Pharmacol. 1996 Aug;48(8):829-33.
27 WO patent application no. 2011,0583,31, Pemirolast for the treatment of systemic low grade inflammation.